## Tyler J Curiel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/939286/publications.pdf

Version: 2024-02-01

124 papers 16,589 citations

53 h-index 108 g-index

125 all docs

125 docs citations

125 times ranked 21211 citing authors

#	Article	IF	CITATIONS
1	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	30.7	4,442
2	Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity. Nature Medicine, 2003, 9, 562-567.	30.7	1,157
3	Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology, 2016, 34, 3119-3125.	1.6	755
4	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal of Experimental Medicine, 2006, 203, 871-881.	8 <b>.</b> 5	638
5	Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Medicine, 2001, 7, 1339-1346.	30.7	603
6	Interventions to Slow Aging in Humans: Are We Ready?. Aging Cell, 2015, 14, 497-510.	6.7	481
7	Tregs and rethinking cancer immunotherapy. Journal of Clinical Investigation, 2007, 117, 1167-1174.	8.2	464
8	Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals. Cancer Research, 2004, 64, 8451-8455.	0.9	395
9	CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression. Cancer Research, 2010, 70, 2245-2255.	0.9	361
10	Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma. Cancer Research, 2005, 65, 5020-5026.	0.9	346
11	CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Research, 2005, 65, 465-72.	0.9	295
12	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Research, 2016, 76, 6964-6974.	0.9	294
13	Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer. Cancer Research, 2004, 64, 5535-5538.	0.9	270
14	Cross-Talk in the Innate Immune System: Neutrophils Instruct Recruitment and Activation of Dendritic Cells during Microbial Infection. Journal of Immunology, 2003, 171, 6052-6058.	0.8	262
15	Regulatory T cells and treatment of cancer. Current Opinion in Immunology, 2008, 20, 241-246.	5 <b>.</b> 5	246
16	Combined autophagy and HDAC inhibition. Autophagy, 2014, 10, 1403-1414.	9.1	240
17	CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. Journal of Clinical Investigation, 2011, 121, 2371-2382.	8.2	221
18	Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential. American Journal of Reproductive Immunology, 2005, 54, 369-377.	1.2	197

#	Article	IF	CITATIONS
19	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood, 2007, 110, 3192-3201.	1.4	177
20	Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discovery, 2017, 7, 72-85.	9.4	153
21	LIVER ALLOTRANSPLANTATION AFTER EXTRACORPOREAL HEPATIC SUPPORT WITH TRANSGENIC (hCD55/hCD59) PORCINE LIVERS. Transplantation, 2000, 69, 272.	1.0	143
22	Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. Cancer Research, 2011, 71, 603-613.	0.9	140
23	Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature, 2021, 599, 673-678.	27.8	139
24	Programmed death ligand 1 signals in cancer cells. Nature Reviews Cancer, 2022, 22, 174-189.	28.4	133
25	Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells. Nature Communications, 2017, 8, 14649.	12.8	128
26	Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by $\hat{l}^2$ -Chemokines Rather Than IL-12. Journal of Immunology, 2000, 165, 4388-4396.	0.8	121
27	B7-H1–Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses. Journal of Immunology, 2010, 185, 2747-2753.	0.8	120
28	Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nature Communications, 2017, 8, 15908.	12.8	118
29	Antiestrogenic Glyceollins Suppress Human Breast and Ovarian Carcinoma Tumorigenesis. Clinical Cancer Research, 2006, 12, 7159-7164.	7.0	107
30	A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Experimental Gerontology, 2018, 105, 53-69.	2.8	107
31	After the Storm — Health Care Infrastructure in Post-Katrina New Orleans. New England Journal of Medicine, 2006, 354, 1549-1552.	27.0	100
32	Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice. Cancer Research, 2012, 72, 2089-2099.	0.9	100
33	Chronic <scp>mTOR</scp> inhibition in mice with rapamycin alters <scp>T</scp> , <scp> B</scp> , myeloid, and innate lymphoid cells and gut flora and prolongs life of immuneâ€deficient mice. Aging Cell, 2015, 14, 945-956.	6.7	94
34	Peptides Identified through Phage Display Direct Immunogenic Antigen to Dendritic Cells. Journal of Immunology, 2004, 172, 7425-7431.	0.8	92
35	Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell–Dependent Mechanism. Cancer Research, 2015, 75, 519-531.	0.9	92
36	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduction and Targeted Therapy, $2016, 1, .$	17.1	83

#	Article	IF	CITATIONS
37	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. Urology, 2014, 83, 863-868.	1.0	82
38	NK Cells Help To Induce CD8+-T-Cell Immunity against Toxoplasma gondii in the Absence of CD4+ T Cells. Infection and Immunity, 2005, 73, 4913-4921.	2.2	80
39	mTORC1 and p53. Cell Cycle, 2013, 12, 20-25.	2.6	79
40	Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Cancer Research, 2017, 77, 1599-1610.	0.9	79
41	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clinical Cancer Research, 2017, 23, 441-453.	7.0	77
42	HIV-Specific Cellular and Humoral Immune Responses in Primary HIV Infection. AIDS Research and Human Retroviruses, 1996, 12, 1129-1140.	1.1	74
43	Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responsesin vivo. European Journal of Immunology, 2004, 34, 66-73.	2.9	70
44	Targeting regulatory T cells. Targeted Oncology, 2012, 7, 15-28.	3.6	67
45	Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. Oncolmmunology, 2018, 7, e1500107.	4.6	66
46	A phosphotyrosine switch determines the antitumor activity of $\text{ER}\hat{l}^2$ . Journal of Clinical Investigation, 2014, 124, 3378-3390.	8.2	65
47	Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. Oncotarget, 2016, 7, 59087-59097.	1.8	65
48	Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. Cancer Research, 2018, 78, 5038-5049.	0.9	64
49	eRapa Restores a Normal Life Span in a FAP Mouse Model. Cancer Prevention Research, 2014, 7, 169-178.	1.5	63
50	TGF- $\hat{l}^2$ -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 2022, 55, 115-128.e9.	14.3	62
51	Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of ILâ€17 producing T cells. Aging Cell, 2012, 11, 509-519.	6.7	61
52	Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer. Oncotarget, 2018, 9, 36492-36502.	1.8	60
53	Inhibition of Human Immunodeficiency Virus-1 Production Resulting from Transduction with a Retrovirus Containing an HIV-Regulated Diphtheria Toxin A Chain Gene. Human Gene Therapy, 1992, 3, 461-469.	2.7	59
54	Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Frontiers in Bioscience - Landmark, 2009, Volume, 1761.	3.0	59

#	Article	IF	CITATIONS
55	Toxoplasma gondii-Infected Human Myeloid Dendritic Cells Induce T-Lymphocyte Dysfunction and Contact-Dependent Apoptosis. Infection and Immunity, 2002, 70, 1750-1760.	2.2	57
56	Optimization of Immunotherapy in Elderly Cancer Patients. Critical Reviews in Oncogenesis, 2013, 18, 573-583.	0.4	55
57	p38 Mitogen-Activated Protein Kinase Stimulates Estrogen-Mediated Transcription and Proliferation through the Phosphorylation and Potentiation of the p160 Coactivator Glucocorticoid Receptor-Interacting Protein 1. Molecular Endocrinology, 2006, 20, 971-983.	3.7	54
58	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory TÂcells. Cancer Cell, 2022, 40, 545-557.e13.	16.8	53
59	Regulatory T-cell development: is Foxp3 the decider?. Nature Medicine, 2007, 13, 250-253.	30.7	52
60	Resident memory CD8+ TÂcells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity, 2021, 54, 2117-2132.e7.	14.3	50
61	Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. International Journal for Parasitology, 2002, 32, 969-977.	3.1	46
62	Progressive increases in serum catalase activity in advancing human immunodeficiency virus infection. Free Radical Biology and Medicine, 1992, 13, 143-149.	2.9	44
63	Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential. Autophagy, 2017, 13, 987-988.	9.1	44
64	Antigen-Specific Immunity and Cross-Priming by Epithelial Ovarian Carcinoma-Induced CD11b+Gr-1+Cells. Journal of Immunology, 2010, 184, 6151-6160.	0.8	42
65	Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis. Clinical Cancer Research, 2011, 17, 2250-2259.	7.0	42
66	Immunotherapy: A useful strategy to help combat multidrug resistance. Drug Resistance Updates, 2012, 15, 106-113.	14.4	42
67	Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii. International Journal for Parasitology, 2004, 34, 1245-1254.	3.1	40
68	High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biology and Therapy, 2005, 4, 289-294.	3.4	37
69	Graft-versus-Host Disease Is Enhanced by Selective CD73 Blockade in Mice. PLoS ONE, 2013, 8, e58397.	2.5	37
70	Toxoplasma gondii Expresses Two Mitogen-Activated Protein Kinase Genes That Represent Distinct Protozoan Subfamilies. Journal of Molecular Evolution, 2007, 64, 4-14.	1.8	36
71	Long-Term Inhibition of Clinical and Laboratory Human Immunodeficiency Virus Strains in Human T-Cell Lines Containing an HIV-Regulated Diphtheria Toxin A Chain Gene. Human Gene Therapy, 1993, 4, 741-747.	2.7	34
72	Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor $\hat{I}^3\hat{I}$ T Cells. Cancer Research, 2016, 76, 5970-5982.	0.9	33

#	Article	IF	CITATIONS
73	Considerations for successful cancer immunotherapy in aged hosts. Experimental Gerontology, 2018, 107, 27-36.	2.8	33
74	Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer. Oncotarget, 2017, 8, 50002-50014.	1.8	32
75	Murder or Mercy? Hurricane Katrina and the Need for Disaster Training. New England Journal of Medicine, 2006, 355, 2067-2069.	27.0	29
76	Parasite Mitogen-Activated Protein Kinases as Drug Discovery Targets to Treat Human Protozoan Pathogens. Journal of Signal Transduction, 2011, 2011, 1-16.	2.0	29
77	p53 and rapamycin are additive. Oncotarget, 2015, 6, 15802-15813.	1.8	29
78	Drugs Designed To Inhibit Human p38 Mitogen-Activated Protein Kinase Activation Treat <i>Toxoplasma gondii</i> li>and <i>Encephalitozoon cuniculi</i> li>Infection. Antimicrobial Agents and Chemotherapy, 2007, 51, 4324-4328.	3.2	27
79	Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication. Experimental Parasitology, 2011, 128, 170-175.	1.2	27
80	Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. Oncolmmunology, 2019, 8, 1614857.	4.6	27
81	Sequential Intravesical Mitomycin plus Bacillus Calmette–Guérin for Non–Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial. Clinical Cancer Research, 2015, 21, 303-311.	7.0	26
82	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Experimental Gerontology, 2018, 105, 146-154.	2.8	26
83	Bladder cancer cellâ€intrinsic PDâ€L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Medicine, 2021, 10, 2137-2152.	2.8	26
84	HIV-Regulated Diphtheria Toxin A Chain Gene Confers Long-Term Protection Against HIV Type 1 Infection in the Human Promonocytic Cell Line U937. Human Gene Therapy, 1995, 6, 1437-1445.	2.7	25
85	Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opinion on Drug Delivery, 2008, 5, 87-103.	5.0	23
86	Immunotherapy for Ovarian Cancer. Current Treatment Options in Oncology, 2015, 16, 317.	3.0	23
87	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor–Induced Synthetic Lethality. Cancer Research, 2022, 82, 2156-2170.	0.9	23
88	Immune Therapy for Ovarian Cancer: Promise and Pitfalls. International Reviews of Immunology, 2011, 30, 102-119.	3.3	21
89	Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. Journal of Biological Chemistry, 2018, 293, 2841-2849.	3.4	21
90	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Research, 2020, 80, 5063-5075.	0.9	21

#	Article	IF	Citations
91	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Research, 2022, 82, 859-871.	0.9	21
92	Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer. Cancer Immunology Research, 2019, 7, 466-475.	3.4	19
93	Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/Oncology Clinics of North America, 2003, 17, 1051-1073.	2.2	18
94	Agingâ€associated B7â€DC <sup>+</sup> B cells enhance antiâ€tumor immunity via Th1 and Th17 induction. Aging Cell, 2012, 11, 128-138.	6.7	18
95	Prevention of Carcinogen and Inflammation-Induced Dermal Cancer by Oral Rapamycin Includes Reducing Genetic Damage. Cancer Prevention Research, 2015, 8, 400-409.	1.5	18
96	Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment. Cancer Research, 2017, 77, 520-531.	0.9	18
97	Rapamycin enhances BCG-specific $\hat{I}^3\hat{I}'$ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. , 2021, 9, e001941.		18
98	Estrogen receptor beta signaling in CD8 <sup>+</sup> T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch., 2021, 9, e001932.		17
99	Tyrosine phosphorylation regulates $\mathrm{ER}^2$ ubiquitination, protein turnover, and inhibition of breast cancer. Oncotarget, 0, 7, 42585-42597.	1.8	16
100	Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. , 2020, 8, e000964.		15
101	TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-Î <sup>3</sup> -mediated nitric oxide production. Experimental Parasitology, 2013, 134, 389-399.	1.2	13
102	PPAR $\hat{l}^3$ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. International Journal of Biological Sciences, 2020, 16, 1526-1535.	6.4	12
103	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from $\hat{l}\pm PD-L1$ and include tissue-selective $\hat{l}^3\hat{l}$ T cell activation., 2021, 9, e002051.		12
104	Tumor immunotherapy: inching toward the finish line. Journal of Clinical Investigation, 2002, 109, 311-312.	8.2	11
105	γδT Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. Cancer Immunology Research, 2021, 9, 1491-1503.	3.4	9
106	Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). British Journal of Cancer, 2022, 127, 1153-1161.	6.4	7
107	IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. Clinical Cancer Research, 2021, 27, 3661-3673.	7.0	6
108	Immune checkpoint expression and relationships to antiâ€PD‣1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. Aging and Cancer, 2022, 3, 68-83.	1.6	5

#	Article	IF	CITATIONS
109	Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. International Journal of Molecular Sciences, 2022, 23, 5129.	4.1	4
110	Manipulating T regulatory cells in cancer immunotherapy. Expert Review of Dermatology, 2006, $1$ , 589-597.	0.3	3
111	Historical Perspectives and Current Trends in Cancer Immunotherapy. , 2013, , 3-15.		3
112	Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. Cell Systems, 2021, , .	6.2	3
113	Abstract LB-259: Interferon-α enhances clinical benefits of regulatory T cell depletion in ovarian cancer through direct T cell effects and by inducing bystander IL-6. Cancer Research, 2014, 74, LB-259-LB-259.	0.9	2
114	Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer. Cancer Immunology, Immunotherapy, 2023, 72, 125-136.	4.2	2
115	CD122-targeted interleukin-2 and $\hat{1}\pm$ PD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. Oncolmmunology, 2021, 10, 2006529.	4.6	1
116	900â€Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner. , 2021, 9, A944-A944.		1
117	242â€Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive. , 2021, 9, A261-A261.		1
118	Abstract LB160: PD-L1-expressing B cells promote murine breast cancer development and mediate the response to anti-PD-L1 immune checkpoint inhibitor to upregulate B-cell CD86 and inhibit tumor growth. , 2021, , .		0
119	Regulatory T Cells in Cancer. , 2012, , 147-173.		0
120	Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules., 2013,, 399-424.		0
121	Targeted Toxins in Cancer Immunotherapy. , 2013, , 377-396.		0
122	Managing Regulatory T Cells to Improve Cancer Immunotherapy. , 2013, , 281-314.		0
123	Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?. , 2018, , 1-18.		0
124	Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?., 2020, , 111-128.		0